Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): commentary, Joks et al.
Gero Joks, Steve Su, Jarrad King
The British journal of psychiatry : the journal of mental science November 1, 2024 DOI: 10.1192/bjp.2024.79 via PubMed
Summary
AI-generated from the abstractA commentary on the KADS study raises concerns about the interpretation of its findings on repeated subcutaneous ketamine injections for treatment-resistant depression. The authors of the commentary aim to clarify points to ensure accurate and balanced information is presented to healthcare professionals, questioning the researchers' discussion of efficacy and safety results from the 4-week randomized double-blind active-controlled trial.
Study at a glance
| Characteristics | Commentary Randomized Double-blind Peer reviewed |
|---|---|
| Topics | Depression Esketamine Ketamine |
| Keywords | Depression/mental health/mental illness Ketamine/esketamine/psychedelics Treatment-resistant depression/trd/refractory depression |
| Key finding | The commentary provides additional perspective on the interpretation of the KADS study's findings regarding efficacy and safety of repeated subcutaneous ketamine for treatment-resistant depression. |
Abstract
Regarding the article, 'Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial', we commend Loo et al for undertaking the Ketamine for Adult Depression Study (KADS). In the interest of ensuring that accurate and balanced information is presented to healthcare professionals on treatment-resistant depression, we raise several points herein to help clarify and provide additional perspective to the researchers' interpretation of their findings in the Discussion.